Acumen Pharmaceuticals Inc

From time to time, our officers (as defined in Rule 16a-1(f)) and directors may enter into Rule 10b5-1 ornon-Rule 10b5-1 trading plans (as each such term is defined in Item 408 of Regulation S-K). The trading plans are intended to satisfy the affirmative defense in Rule 10b5-1(c). During the three months ended September 30, 2024, our officers and directors took the following actions with respect to 10b5-1 trading plans:

On August 30, 2024, Matthew Zuga, our Chief Financial Officer and Chief Business Officer, entered into a Rule 10b5-1 trading plan that provides that Mr. Zuga, acting through a broker, may sell the number of shares of common stock sufficient to cover the taxes solely associated with the vesting of up to 128,334 restricted stock unit (“RSU”) awards granted to Mr. Zuga as equity compensation, which sales may occur from January 3, 2025 to December 31, 2027. On September 24, 2024, Mr. Zuga entered into a separate 10b5-1 trading plan that provides that Mr. Zuga, acting through a broker, may sell (1) up to 83,110 shares of common stock, which sales may occur from January 23, 2025 through January 16, 2026; (2)594,663 shares of common stock received upon the exercise of option awards granted to Mr. Zuga as equity incentive compensation, which sales may occur from January 23, 2025 through January 16, 2026; and (3)46,501 shares of common stock received upon the vesting of RSU awards granted to Mr. Zuga as equity incentive compensation, which sales may occur from January 23, 2025 to January 16, 2026.

On August 31, 2024, Russell Barton, our Chief Operating Officer, entered into a Rule 10b5-1 trading plan that provides that Mr. Barton, acting through a broker, may sell the number of shares of common stock sufficient to cover the taxes associated with the vesting of up to 90,800 RSU awards granted to Mr. Barton as equity compensation, which sales may occur from January 3, 2025 to December 31, 2027.

On September 3, 2024, Eric Siemers, M.D., our Chief Medical Officer, entered into a Rule 10b5-1 trading plan that provides that Dr. Siemers, acting through a broker, may sell the number of shares of common stock sufficient to cover the taxes associated with the vesting of up to 111,800 RSU awards granted to Dr. Siemers as equity compensation, which sales may occur from January 3, 2025 to December 31, 2027.